The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells

The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells

Abstract Trastuzumab deruxtecan (T-DXd), a HER2-targeting antibody–drug conjugate with a topoisomerase I inhibitor deruxtecan (DXd), exhibits an excellent anti-tumor effect in previously treated HER2-positive tumors. A recent study demonstrated that T-DXd not only suppressed tumor growth but also en...

Full description

Bibliographic Details
Main Authors: Shotaro Nakajima, Kosaku Mimura, Takuro Matsumoto, Aung Kyi Thar Min, Misato Ito, Hiroshi Nakano, Prajwal Neupane, Yasuyuki Kanke, Hirokazu Okayama, Motonobu Saito, Tomoyuki Momma, Yohei Watanabe, Hiroyuki Hanayama, Suguru Hayase, Zenichiro Saze, Koji Kono
Format: Article
Language:English
Published: Nature Publishing Group 2021-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-96521-2

Internet

https://doi.org/10.1038/s41598-021-96521-2

Similar Items